Kornimate/medical-research-clean huggingface dataset:
use of oxybutynin to treat axillary hyperhidrosis

Conditions: Axillary Hyperhidrosis; Osmidrosis

Summary: the objective of this study was to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses for treating axillary hyperhidrosis in a large series of patients.


Eligibility criteria:
inclusion criteria: * patients with axillary hyperhidrosis exclusion criteria: * glaucoma and micturition disorders, pregnancy

Keywords: hyperhidrosis axillary osmidrosis oxybutynin
phase 3 efficacy and safety study of gtx-102 in pediatric subjects with as

Conditions: Angelman Syndrome

Summary: the primary objective of this study is to evaluate the effect of gtx-102 in cognitive function in participants with deletion-type angelman syndrome (as).


Eligibility criteria:
key inclusion criteria: * signed informed consent from parent(s) or legal guardian(s) * confirmed diagnosis of as with genetic confirmation of full maternal ubiquitin-protein ligase e3a (ube3a) gene deletion causing as in the region of 15q11.2 q13 * able to ambulate independently, or with assistance at the screening visit (note, a child whose primary means of mobility is by wheelchair is excluded from the study) * platelet count, prothrombin time / international normalized ratio, and partial thromboplastin time within 1.5x the normal limits at the screening visit * willing and able to comply with scheduled visits, drug administration plan, laboratory tests, and all study procedures, including lp procedure, mri, and tolerating anesthesia without intubation * from the time of informed consent through to at least 6 months after the final dose of gtx-102, females of childbearing potential who are sexually active must use highly effective contraception or abstinence. males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of gtx-102 key exclusion criteria: * any change in medications or diet/supplements intended to treat symptoms of as (eg, sleeping aids, antiseizure medications, supplements, dietary change including ketogenic or low-glycemic index diet, other) within the month prior to the screening visit (excluding weight-based adjustments) * any condition that creates an increased risk of unsuccessful lp * current or expected concomitant use of drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors) * known hypersensitivity to gtx-102 or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects * presence or history of any condition, lab abnormality, or infection, that, in the judgement of the investigator, would interfere with participation, pose undue safety risk, or would confound interpretation of results * pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study * use of any investigational product or investigational medical device within 6 months or 5 half-lives prior to the screening visit or any prior use of gene therapy or aso regardless of duration since last administration * concurrent participation in any interventional study
lenalidomide dose escalation combined with rituximab/fludarabine in untreated cll

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Summary: the aim of this study is to determine the maximal tolerated dose level of lenalidomide combined with fludarabine/rituximab in the therapy of patients with previously untreated cd20-positive chronic lymphocytic leukemia. following a dose escalation phase lenalidomide will be given at the pre-determined maximum tolerated dose in combination with rituximab to further determine the efficacy and tolerability of this regimen.

this is a non-randomized, multicenter, open-label, single-arm phase i/ii study in patients with previously untreated cd20-positive cll. phase i of the study will evaluate the maximal tolerated lenalidomide dose level in combination with fludarabine/rituximab chemoimmunotherapy in 10 patients. phase ii will determine efficacy using the combination in the previously defined maximal tolerated dose. both phases will be followed by a maintenance phase evaluating the tolerability and possibility to further improve response quality.

Eligibility criteria:
inclusion criteria: * b-cll (cd23+, cd5+, cd19+, cd20+) * treatment indication according to nci criteria * age \>= 18 yrs * no previous treatment of cll by chemo-, radio- or immunotherapy * life expectancy \> 6 months * written informed consent * women of non-childbearing potential or women of childbearing potential and men using effective contraception exclusion criteria: * active bacterial, viral or fungal infection * positivity for hiv, hepatitis b or c * reduce organ functions and bone marrow dysfunction not due to cll * creatinine clearance below 30 ml/min * patients with medical conditions requiring long-term use of systemic corticosteroids during study treatment * patients with a history of severe cardiac disease * other known co-morbidity with the potential to dominate survival * transformation to aggressive b-cell malignancy * known hypersensitivity to humanised monoclonal antibodies or any of the study drugs * pregnant or breast-feeding women * any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

Keywords: cll untreated immune therapy dose escalation maximum tolerated dose maintenance therapy lenalidomide rituximab fludarabine
physical therapy vs arthroscopic partial meniscectomy

Conditions: Knee Medial Meniscus Tears

Summary: the purpose was to assess knee function outcomes between physical therapy and arthroscopic partial menisectomy(apm) for metabolic syndrome(mets) patients with degenerative meniscus lesions(dmls) during 12 month follow up.

metabolic syndrome were diagnosed with abdominal obesity, insulin resistance with or without glucose intolerance, dyslipidemia or elevated blood pressure and widely prevalence all around the world.mets patients were always correlated with knee osteoarthritis or cartilage volume loss. for mets patients with dmls, whether physical therapy was non-inferior to apm in knee function and mets components was unknown.

Eligibility criteria:
inclusion criteria: * must be age between 35 and 70 years old; * clinical diagnosis of metabolic syndrome; * clinical diagnosis of degenerative meniscus lesions; * patients who has knee pain history * knee symptoms consistent with dmls verified on mri * eligible for arthroscopic partial meniscectomy surgery by the examining orthopedic surgeons. exclusion criteria: * must be able to have no acute knee injury such as car crash or acute sports injury; * must be able to have no knee surgeries history; * must be able to have no rheumatoid arthritis or serious knee osteoarthritis with deformity; * must be able to have no contraindications to mri; * must be able to have no severe cardiopulmonary disease; * must be able to have no musculoskeletal or neuromuscular impairments ; * must be able to have good visual, hearing, or cognitive;
central sensitization symptoms and psychosocial factors in athletes after acl reconstruction

Conditions: Anterior Cruciate Ligament Rupture

Summary: the main research objective of this study is whether athletes who have sustained an anterior cruciate ligament injury, experience chronic nociplastic pain and psychosocial factors, including kinesiophobia and pain catastrophizing, after having been through acl reconstruction surgery and rehabilitation and have returned to sport.

this is an observational, cross-sectional study. for the purposes of the study a sample group was selected from a clinic specialised in acl reconstruction and rehabilitation based in athens, greece. patients of the specific clinic had received the same surgical technique and rehabilitation protocol. ability to return to sport was examined 9 months after surgery and approval was given according to the rehabilitation progress. a list of eligible study subjects was formed and, after inclusion and exclusion criteria were screened for, they were invited to participate in the study. study participants, after having declared consent and passed the criteria were asked to answer the study questionnaires. communication with participants was done through telephone and email, and all questionnaires were completed online.

Eligibility criteria:
inclusion criteria: 1. knowledge of greek language, 2. surgically reconstructed acl tear on one limb only, 3. successful completion of rehabilitation program, 4. medical permission to return to sport, 5. returned to previous sport for at least 6 months period 6. athlete of a lower limb loading sport. exclusion criteria: 1. adolescent age (\<18 years of age), 2. diagnosis of cancer of any stage, 3. diagnosis of psychiatric, neurological or autoimmune disease or syndrome, 4. past musculoskeletal injuries, including fractures, joints dislocation, ligament and tendon tears and 5. chronic musculoskeletal injuries (tendinopathies, shin splints, shoulder impingement etc.). chronic pain is defined as pain persisting for at least 3 months, of intensity at least 3 on the vas scale for most days per week (kuppens et al. 2018).

Keywords: return to play psychosocial central sensitization chronic pain athlete reconstruction rehabilitation
the effects of playing high school football on later life cognitive functioning and mental health

Conditions: Memory Impairment; Executive Dysfunction; Depression

Summary: the purpose of this study is to assess the effect of playing high school football on later in life cognitive functioning and mental health. this is an observational study that will use data from the wisconsin longitudinal study to compare high school football playing graduates in 1957 with comparable non-high school football playing graduates on cognitive functioning and mental health measures when participants are in their 60s.

the investigators will use data from the wisconsin longitudinal study (wls) of graduates from wisconsin high schools in 1957 to investigate the link between playing high-school football and later life depression and cognitive impairment. the wls has a number of attractive features that make it well-suited for such a study. first, it records whether study participants participated in high school football and also includes detailed measurements of later-life mental health, psychological well-being, and cognition. second, it includes a rich set of baseline covariates which the investigators will use to construct matched sets of treated and control individuals, including family background, adolescent characteristics, educational and occupational achievement and aspirations. third, the wls is one of the few longitudinal data sets that includes an administrative measure of childhood cognition. in short, the wls provides a large data set that facilitates comparing the later life mental health and cognitive ability of men who played high school football to those who did not, after carefully controlling for a range of potential confounders. the investigators will compare the primary outcomes of the treated subjects to the primary outcomes of the control subjects, after controlling for baseline covariates via full matching with a propensity score caliper. the primary outcomes are depression (modified ces-d score) and cognitive functioning (average of z-scores for letter fluency and delayed word recall) when participants are age 65. secondary outcomes that include cognitive scores on various domains, the spielberger anger index, the spielberger anxiety index and a hostility index will also be analyzed.

Eligibility criteria:
inclusion criteria: -- male. exclusion criteria: * no yearbook information available to determine football playing status * activity participation in yearbook was not recorded under senior photo or in an index. * did not played football but played another high contact sport (soccer, hockey, lacrosse or wrestling).
effect of ginseng on glycemic control

Conditions: Impaired Glucose Tolerance; Diabetes

Summary: ginseng (american ginseng, asian ginseng, korean ginseng etc) is expected to show positive hypoglycemic effects, including improvements in glycated blood proteins\[hba1c\], fasting glucose, fasting insulin, and the homeostasis model assessment of insulin resistance \[homa-ir\]).

ginseng has demonstrated to have significant hypoglycemic effect. its major pharmacological component is considered to be ginsenosides. several trials have been undertaken in diabetes some of which have demonstrated advantages in glycemic control in both diabetic as well as non diabetic individuals although clinical consistency of results is lacking.the lack of high quality data in this area to support diabetes recommendations represents an urgent call for stronger evidence. a systematic review and meta-analysis of controlled trials remains the "gold standard" of evidence for recommendations and clinical guidelines development. therefore, investigators will conduct a systematic review and meta-analyses of controlled trials to assess the effect of ginseng on glycemic control.

Eligibility criteria:
inclusion criteria: * dietary trials in humans * randomized treatment allocation * 1 month * suitable control * viable endpoint data exclusion criteria: * non-human studies * non-randomized treatment allocation * \<1 month * lack of a suitable control * no viable endpoint data
treadmill training for spinal cord injury

Conditions: Spinal Cord Injury

Summary: this is a trial to test whether treadmill training can be used to improve the "walking" of patients with partial spinal cord injury. while on the treadmill, patients will be partially supported through the use of a specially designed harness attached to an overhead lift (also called body weight supported treadmill training, bwstt). patients who enroll in this study will be randomly assigned to either the experimental group, which receives 12 weeks of this specialized treadmill training with regular physical therapy, or to the control group, which receives 12 weeks regular physical therapy. the ability of the patients to "walk" will be measured before and after treatment as well as 6 and 12 months later, using standard tests that examine mobility independence and speed of ambulation. the trial takes place across five sites in the us and canada. patients eligible for this trial will have had a traumatic spinal cord injury within 8 weeks of trial entry.

this is a 5-site randomized clinical trial of a task-oriented locomotor intervention for acute spinal cord injury (sci). the intervention, body weight-supported treadmill training (bwstt), partially supports the weight of the patient via an overhead lift attached to a harness. therapists train the patient to walk on a treadmill by correcting gait deviations and manipulating sensory input that enhance control of the stance and swing phases of walking at increasingly higher speeds and less weight support. 100 patients with incomplete sci (from below c4 to t10/11) and 100 patients with lesions at t12 to l3 will be randomly assigned to 12 weeks of conventional therapy programs for mobility versus the same intensity and duration of a combination of conventional therapy plus bwstt. the primary outcome measures are the level of independence for ambulation and the maximal speed for walking 50 feet. patients will be tested by masked examiners before and after the 12 weeks of therapy, and 6 and 12 months after entry into the study.

Eligibility criteria:
inclusion criteria: * traumatic spinal cord injury (within 56 days) * incomplete lesion: - asia c or d, from below c4 to l3 - asia b at or below c7 * unable to ambulate over ground without at least moderate assistance (fim locomotor 3 or less) * able to offer at least 3/5 strength in elbow extensors * no clinically-significant cognitive impairment exclusion criteria: * symptomatic fall in blood pressure greater than 30 mm hg when upright * halo or other cervical brace or tlso (unless primary surgeon agrees) * contraindication to weight bearing on lower extremities * pressure sore with any skin breakdown below level of the sci * any debilitating disease prior to the acute sci that would cause exercise intolerance * premorbid, ongoing major depression or psychosis * required use of anti-spasticity medication * subject unlikely to complete intervention or return for follow-up

Keywords: spinal cord injury body weight supported ambulation training treadmill training physical therapy gait assisted ambulation
sucrosomial iron on insomnia in non-dialysis chronic kidney disease patients with iron deficiency anemia

Conditions: CKD; Sleep Disorder

Summary: insomnia or sleep disturbance is a common disorder in patients with chronic kidney disease (ckd), but is often unrecognized and undertreated. it is known that sleep disorders may indirectly cause a variety of diseases and affect quality of life. the most common sleep disorders that occur in ckd are insomnia, excessive daytime sleepiness, obstructive or central sleep apnea (sa), and sleep disorders. this study evaluates the effectiveness and safety of sideral® sucrosomial iron and iron chewable tablets 100mg commonly used in health insurance on sleep disorders in patients with ckd and iron deficiency anemia.


Eligibility criteria:
inclusion criteria: 1. adults aged 20-80. 2. chronic kidney disease (ckd) patients. 3. iron deficiency anemia (male haemoglobin (hb) ≤13 g/dl; female haemoglobin (hb) ≤12 g/dl, ferritin ≤100 ng/ml, transferrin saturation ≤25%). 4. patients diagnosed as chronic insomnia by doctors according to international classification of sleep disorders-third edition (icsd-3). 5. subjects who voluntarily participate in the trial plan and complete the consent form after explanation by doctors or project personnel. exclusion criteria: 1. patients taking iron supplements. 2. patients with non-chronic insomnia. 3. patients with alcoholism within one year. 4. people with other serious diseases. 5. pregnant women or women who are still breastfeeding. 6. those who are unable to cooperate with the test progress. 7. patients with autoimmune abnormalities (ex. inflammatory bowel disease). 8. people with non-iron deficiency anemia (ex. thalassemia). 9. those who are taking sleeping pills or sedatives.
the use of a water soluble under the tongue (sublingual) cbd tablet for treating pain associated with diabetic peripheral neuropathy

Conditions: Diabetic Neuropathies

Summary: use of cannabidiol for the treatment of diabetic neuropathic pain.


Eligibility criteria:
inclusion criteria: 1. subject is at least 21 years of age; 2. subject has a diagnosis of chronic diabetic neuropathic pain condition as determined by the subject's health care or allied health provider for which medications other than cannabis, cannabinoids, or cannabis-based medicines are currently utilized; 3. subject has a 7-day average pain scale score (recorded during the screening period) of ≥ 5; 4. if female, subject is postmenopausal (\> 1 year), surgically sterile, or practicing an approved method of birth control throughout the study and for 5 months (150 days) after the last dose of study drug; 5. if female and of childbearing potential, subject has a denied pregnancy and has no desire to become pregnant throughout the duration of the study; 6. subject is willing and able to provide his/her written informed consent to participate in the study as stated in the informed consent document; 7. subject has access to a smart phone and knows how to use smart phone applications. exclusion criteria: 1. subject is pregnant or lactating; 2. subject has an allergy to cannabis, the cannabaceae plant family (e.g., hemp, hops, hackberry), pea, terpenes, peppermint; 3. subject has a known allergy to active or inert ingredients of pure green tablets; 4. subject is currently treating their pain with cannabis, cannabinoids, cannabis-base medicine; 5. subject is taking a concomitant medication or treatment that would complicate use or interpretation of the study drug's effects (examples include: cannabis or any cannabinoid products; any drug or herbal product that influences the endocannabinoid system (ecs)); 6. subject is taking marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or cbd for at least 30 days prior to this study., and does not promise to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or cbd while participating in this study; 7. subject is currently being treated with antibiotics for sinus, throat, or lung infections; 8. subject has shortness of breath associated with allergies; 9. subject has uncontrolled asthma; 10. subject has a fever and/or productive cough; 11. subject does not have access to a smart phone or does not know how to use a smart phone application.

Keywords: pain neuropathy neuropathic pain diabetes
alzheimer's disease and related dementias (adrd) prevalence in american samoa

Conditions: Alzheimer's Disease and Related Dementia

Summary: the goal of this study is to learn about adrd prevalence within the samoan population. participants will be administered a series of cognitive assessments to determine cognitive status and a population-based prevalence of mild cognitive impairment (mci) and adrd. blood samples will also be collected from the participants for genetic and plasma biomarker analysis.

this study aims to do the following: test adrd knowledge, health literacy, research readiness and determine adrd resilience and vulnerability factors, and cognitive status in a probability sample of 981 samoans age 50+ using culturally adapted instruments in our probability sample. conduct gold standard evaluations in our probability sample using the uniform data set (udsv3.0) from the national institute on aging (nia) alzheimer's disease research center program to determine a population-based prevalence of mci and adrd for harmonization, data sharing, and comparison to other groups, and, cross-validate gold standard dementia evaluations with genetic (i.e., apoe) and plasma amyloid-tau-neuronal injury/neurodegeneration (atn) framework biomarkers in our probability sample and compare to information available for other racial/ethnic groups.

Eligibility criteria:
inclusion criteria: * age 50 or older * community dwelling * speaks english or samoan * willing to contribute a biomarker specimen exclusion criteria: * residing in assistant living or skilled nursing facility * axis 1 psychiatric diagnosis (e.g., schizophrenia, bipolar) * unstable medical condition (i.e., metastatic cancer) that could preclude completion of study visit